8-K: Apimeds Pharmaceuticals Appoints Veteran Financial Executive Erick J. Frim as New Chief Financial Officer

Apimeds Pharmaceuticals US, Inc. has announced the appointment of Erick J. Frim, a financial executive with over 40 years of experience, as its new Chief Financial Officer, replacing Mark Corrao.

Summary

• Apimeds Pharmaceuticals US, Inc. (the "Company") appointed Erick J. Frim as its new Chief Financial Officer on May 30, 2025.
• Mr. Frim, aged 67, brings over 40 years of experience in financial management and operations to the role.
• He replaces Mark Corrao as CFO.
• Prior to this appointment, Mr. Frim served as Interim Chief Financial Officer of Helio Corporation since December 2024.
• He is also a partner at CFO Squad, LLC, where he oversees SEC reporting and technical accounting practices, a position he has held since 2019.
• His extensive background includes directorships at SolomonEdwardsGroup, LLC and EisnerAmper, LLP, and a previous role as VP and CFO of DIVA Systems Corporation.
• Mr. Frim is a former CPA and holds a bachelor's degree in Accounting and a master's degree in Organization Dynamics.
• In connection with his appointment, the Company entered into a one-year consulting agreement with Mr. Frim on June 4, 2025, providing for a base fee of $2,500 per month for eight hours of service, with an additional fee of $250 per hour for work exceeding this amount.
• There are no familial relationships between Mr. Frim and any executive officer or director of the Company, nor has he engaged in any reportable related party transactions.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced and qualified Chief Financial Officer is a positive development for the company, indicating a focus on strengthening financial leadership and compliance.

Positives

• The appointment of Erick J. Frim, with over 40 years of extensive experience in financial management, operations, SEC reporting, and technical accounting, significantly strengthens the Company's executive team.
• Mr. Frim's background as a former CPA and his roles at reputable firms like EisnerAmper, LLP and CFO Squad, LLC, indicate a strong foundation in financial compliance and strategic oversight.
• His recent experience as Interim CFO of Helio Corporation demonstrates current and relevant executive leadership capabilities.

Future Outlook

The document does not provide specific forward-looking statements or financial guidance beyond the term of the consulting agreement for the new CFO.

Management Comments

• Erik Emerson, Chief Executive Officer, signed the report on behalf of Apimeds Pharmaceuticals US, Inc.

Industry Context

The appointment of a seasoned financial executive like Mr. Frim is a common strategic move for pharmaceutical companies, particularly those navigating complex regulatory environments and seeking to optimize financial operations and reporting. His experience in SEC reporting is particularly relevant for a publicly traded entity in a highly regulated industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO may instill greater confidence in the company's financial management and reporting, potentially positively influencing investor sentiment.
• Employees: A strong financial leader can contribute to stable and well-managed corporate operations, which can benefit employees through improved organizational efficiency.
• Creditors: Enhanced financial oversight by an experienced CFO can improve the company's financial credibility and risk management, which is favorable to creditors.

Next Steps

• The consulting agreement with Erick J. Frim has a term of one year, indicating his initial engagement period as CFO.

Key Dates

Keywords

Apimeds Pharmaceuticals, CFO appointment, Chief Financial Officer, Erick J. Frim, executive change, financial management, SEC reporting, corporate governance, pharmaceuticals, 8-K filing